LINKER-MM4
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma
What will happen during the trial?
The primary objectives of the study are:
For Phase 1
- To find out if linvoseltamab is safe and well tolerated
- To find out what the most appropriate dosing schedule would be for future clinical trials
For Phase 2
- To find out if it works to treat multiple myeloma
The secondary objectives of the study are:
For Phase 1 and 2
- To find out how linvoseltamab moves throughout the body over time (pharmacokinetics)
- To find out how much B-cell maturation antigen (BCMA) participants have in their blood
- To find out if the participants' immune systems respond to linvoseltamab.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 132 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1479
- NCT Identifier
- NCT05828511
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.